Antilipemic agent: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett mNo edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[medicine]], '''antilipemic agents''' are [[medication]]s for the treatment of [[hypercholesterolemia]] and [[hypertriglyceridemia]].<ref>{{MeSH}}</ref> | In [[medicine]], '''antilipemic agents''' are [[medication]]s for the treatment of [[hypercholesterolemia]] and [[hypertriglyceridemia]].<ref>{{MeSH}}</ref> | ||
==Classification== | ==Classification== | ||
===Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins)=== | |||
{{main|Hydroxymethylglutaryl-coenzyme A reductase inhibitor}} | |||
===Bile acid sequestrants=== | |||
===Fibric acid derivatives=== | |||
[[Clofibric acid]] derivatives include [[gemfibrozil]], [[clofibrate]], and [[fenofibrate]]. [[Fenofibrate]] is unique in being able to lower the serum [[uric acid]] level and treat [[hyperuricemia]].<ref name="pmid12595630">{{cite journal |author=Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA |title=Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout |journal=Rheumatology (Oxford) |volume=42 |issue=2 |pages=321–5 |year=2003 |month=February |pmid=12595630 |doi= |url=http://rheumatology.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12595630 |issn=}}</ref> | |||
===Plant stanols=== | |||
==Uses== | |||
{{main|Hypercholesterolemia|Hypoalphalipoproteinemia}} | |||
==Adverse effects== | |||
Medications, such as the antilipemic agents [[atorvastatin]], [[simvastatin]], or [[gemfibrozil]] that are metabolized by [[cytochrome P-450]] may increase bleeding when added to patients taking [[warfarin]].<ref name="pmid20103024">{{cite journal| author=Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S| title=Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. | journal=Am J Med | year= 2010 | volume= 123 | issue= 2 | pages= 151-7 | pmid=20103024 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=20103024 | doi=10.1016/j.amjmed.2009.07.020 | pmc=PMC2813204 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Latest revision as of 07:30, 11 May 2010
In medicine, antilipemic agents are medications for the treatment of hypercholesterolemia and hypertriglyceridemia.[1]
Classification
Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins)
Bile acid sequestrants
Fibric acid derivatives
Clofibric acid derivatives include gemfibrozil, clofibrate, and fenofibrate. Fenofibrate is unique in being able to lower the serum uric acid level and treat hyperuricemia.[2]
Plant stanols
Uses
Adverse effects
Medications, such as the antilipemic agents atorvastatin, simvastatin, or gemfibrozil that are metabolized by cytochrome P-450 may increase bleeding when added to patients taking warfarin.[3]
References
- ↑ Anonymous (2024), Antilipemic agent (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA (February 2003). "Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout". Rheumatology (Oxford) 42 (2): 321–5. PMID 12595630. [e]
- ↑ Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S (2010). "Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk.". Am J Med 123 (2): 151-7. DOI:10.1016/j.amjmed.2009.07.020. PMID 20103024. PMC PMC2813204. Research Blogging.